These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22451133)

  • 41. Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.
    Johnson KP
    Expert Rev Neurother; 2012 Apr; 12(4):371-84. PubMed ID: 22449210
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.
    Hernandez L; Guo S; Toro-Diaz H; Carroll S; Syed Farooq SF
    J Med Econ; 2017 Mar; 20(3):228-238. PubMed ID: 27730845
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
    Kobelt G; Berg J; Lindgren P; Jonsson B; Stawiarz L; Hillert J
    Mult Scler; 2008 Jun; 14(5):679-90. PubMed ID: 18566030
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Routine interferon-neutralising antibody testing in patients with relapsing-remitting multiple sclerosis.
    Foley P; Reilly P; Coulson A; O'Riordan JI
    J R Coll Physicians Edinb; 2010 Jun; 40(2):105-10. PubMed ID: 21125049
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
    Agashivala N; Kim E
    Clin Ther; 2012 Jul; 34(7):1583-90. PubMed ID: 22749258
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis.
    Murdoch D; Lyseng-Williamson KA
    BioDrugs; 2005; 19(5):323-5. PubMed ID: 16207073
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Cost-utility analisys of multiple sclerosis treatment with glatiramer acetate or interferon beta in Spain].
    Rubio-Terrés C; Arístegui Ruiz I; Medina Redondo F; Izquierdo Ayuso G
    Farm Hosp; 2003; 27(3):159-65. PubMed ID: 12835817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
    Thouvenot E; Carlander B; Camu W
    Expert Rev Neurother; 2012 Nov; 12(11):1283-91. PubMed ID: 23140228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
    Saida T; Kira J; Ueno Y; Harada N; Hirakata T
    Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
    Lanzillo R; Quarantelli M; Pozzilli C; Trojano M; Amato MP; Marrosu MG; Francia A; Florio C; Orefice G; Tedeschi G; Bellantonio P; Annunziata P; Grimaldi LM; Comerci M; Brunetti A; Bonavita V; Alfano B; Marini S; Brescia Morra V;
    Mult Scler; 2016 Aug; 22(9):1163-73. PubMed ID: 26466947
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NICE rules out NHS prescription of fingolimod for multiple sclerosis.
    Cohen D
    BMJ; 2011 Aug; 343():d5117. PubMed ID: 21831936
    [No Abstract]   [Full Text] [Related]  

  • 54. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    BioDrugs; 2003; 17(3):207-10. PubMed ID: 12749757
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis.
    Rinaldi F; Perini P; Calabrese M; Rinaldi L; Gallo P
    Mult Scler; 2009 Nov; 15(11):1359-62. PubMed ID: 19812116
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial.
    Chataway J; Porter B; Riazi A; Heaney D; Watt H; Hobart J; Thompson A
    Lancet Neurol; 2006 Jul; 5(7):565-71. PubMed ID: 16781986
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL; Scott LJ
    CNS Drugs; 2004; 18(8):521-46. PubMed ID: 15182221
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.
    Voloshyna N; Havrdová E; Hutchinson M; Nehrych T; You X; Belachew S; Hotermans C; Paes D
    Eur J Neurol; 2015 Mar; 22(3):570-7. PubMed ID: 25511792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.